to Content

MSc. FRCP Anthony HOWELL Professor of Medical Oncology; Director, Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, University of Manchester

CV

 Anthony Howell is Professor of Medical Oncology and is the Director of the Breakthrough Breast Cancer Research Unit, University of Manchester. Formerly he was Chairman of the UKCCCR - United Kingdom Coordinating Committee on Cancer Research, the British Breast Group and the Manchester Breast Centre, was the Research and Development Director of The Christie NHS Foundation Trust and the Cancer Research Network. His interests are the endocrine therapy and biology of the breast and breast cancer with a particular interest in prevention. He has published over 500 papers mainly in these areas. He is also principal investigator on several clinical trials, including those developing 'pure' antioestrogens.

Memberships

Chairman, United Kingdom Coordinating Committee for Cancer Research Breast Groups
Chairman, European School of Oncology (ESO) Breast Cancer Task Force

Publications

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. Howell A, Roberston JF, Abram P, Lichinister MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. J Clin Oncol. 22 (9):1605-13, 2004
Association of gain and loss of weight before and after menopause with risk of breast cancer in the Iowa Womens Health Study (IWHS). Harvie M, Howell A, Vierkant R, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA. Cancer Epidemiol Biomarkers & Prev. 14 (3): 656-61, 2005
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists Group. Lancet 365:60-62, 2005
Long-term results of tamoxifen prophylaxis for breast cancer - 96 month follow-up of the IBIS-I study. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A. Journal of National Cancer Institute. 99 (4): 272-282, 2007